COMMUNIQUÉS West-GlobeNewswire

ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion
23/02/2026
ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced [...]
Transactions in Connection with Share Buy-back Program
23/02/2026
Company Announcement COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a [...]
Nucleus Upgrades Preview, The First True Glimpse of Your Future Child
23/02/2026
Couples can now model 100 potential children across rare and common diseases, offering the most complete picture of inheritance yet. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today introduced Preview [...]
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Editas Medicine to Participate in Upcoming Investor Conferences
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation in one-on-one [...]
Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible [...]
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” [...]
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
23/02/2026
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS ), a clinical- [...]
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the [...]
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
23/02/2026
Dr. Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, brings leadership experience spanning approximately 50 regulatory approvals and over $100 billion in [...]
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
23/02/2026
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin [...]
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
23/02/2026
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ [...]
Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer
23/02/2026
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab 1 ,2,3,4,5 SC amivantamab is now authorised across all previously [...]
J-Star Signs Exclusive Distribution Agreement with PSSB
23/02/2026
TAICHUNG CITY, Taiwan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse [...]

Pages